Status:
COMPLETED
SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease
Lead Sponsor:
Desitin Arzneimittel GmbH
Conditions:
Parkinson's Disease
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the non-interventional Post Marketing Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Mor...
Eligibility Criteria
Inclusion
- Male and female patients 18 years and older.
- Indication: Morbus Parkinson.
- Treatment with piribedil for the first time.
- Monotherapy with piribedil.
- Combination therapy with L-Dopa (from the beginning or secondary) and/or in combination with other antiparkinsonian drugs.
Exclusion
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00725478
Start Date
January 1 2008
End Date
June 1 2008
Last Update
March 31 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.